

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

PACIFIC BIOSCIENCE  
LABORATORIES, INC., a Washington  
corporation,

Plaintiff,

v.

ANEX CORPORATION, a Korean  
corporation,

Defendant.

No.

COMPLAINT FOR PATENT  
INFRINGEMENT

**JURY DEMAND**

Plaintiff Pacific Bioscience Laboratories, Inc. (“PBL”), for its Complaint for Patent Infringement against Defendant ANEX Corporation, (“ANEX”), hereby alleges, by and through its attorney, on personal knowledge as to its own actions and on information and belief as to the actions of others, as follows:

**I. INTRODUCTION**

1. Plaintiff PBL dramatically changed the market for skin cleansing products when it introduced its innovative Clarisonic Sonic Skin Cleansing System (the “Clarisonic System”) in 2004. The Clarisonic System employs motion and forces at sonic frequencies to cleanse, soften, and smooth skin.



1 and belief, ANEX also has a place of business at #304-705 Bucheon Techno Park, 345  
2  
3 Seokcheon-ro, Ojeong-gu, Bucheon City, Gyenggi-do 421-741, Korea.

4  
5 11. On information and belief, ANEX manufactures, markets, and sells electric skin  
6  
7 care devices under the name Mimian.

8  
9 **III. JURISDICTION AND VENUE**

10  
11 12. This case arises under the patent laws of the United States, 35 U.S.C. § 101 et seq.

12  
13 13. The Court has subject matter jurisdiction over this case pursuant to 28 U.S.C.  
14  
15 §§ 1331, 1332, and 1338.

16  
17 14. PBL has its principal place of business in this District, and makes its Clarisonic  
18  
19 devices available for sale in this District.

20  
21 15. This Court has personal jurisdiction over ANEX because, on information and  
22  
23 belief, ANEX has committed and continues to commit the acts violating PBL's intellectual  
24  
25 property described herein within the State of Washington, including in this District, and places  
26  
27 infringing products into the stream of commerce, with the knowledge or understanding that such  
28  
29 products are sold in the State of Washington, including in this District.

30  
31 16. Venue is proper in this District pursuant to 28 U.S.C. § 1391(b), (c), and 28  
32  
33 U.S.C. § 1400(b) because, *inter alia*, PBL's principal place of business is within this District and  
34  
35 PBL suffered harm in this District, because a substantial part of the events giving rise to the  
36  
37 claims against ANEX occurred and are occurring in this District, and because ANEX transacts  
38  
39 business within this District and offers for sale in this District products that infringe PBL's  
40  
41 intellectual property.

42  
43 **IV. BACKGROUND**

44  
45 17. Since the early 2000s, PBL has designed, developed, manufactured, marketed,  
46  
47 and sold in the United States (and worldwide) its innovative Clarisonic System, which is a line of  
48  
49 skin care products including a number of Sonic Cleansing Brushes and accessories, the  
50  
51

1 Clarisonic Opal® Sonic Infusion System, and targeted treatment solutions. Examples of  
2  
3 Clarisonic products are pictured below:  
4



5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 18. The Clarisonic System was developed by PBL over many years at great expense  
22 and effort and represents a breakthrough in devices and methods for treatment of early stage acne  
23 and for effective cleansing of skin. Those devices and methods employ motion and forces at  
24 sonic frequencies to cleanse, soften, and smooth skin. They alleviate clogged pores and remove  
25 debris from skin more gently and effectively than alternative devices or methods, such as manual  
26 cleansing.  
27  
28  
29  
30  
31

32  
33 19. The innovations embodied in the Clarisonic System are protected by numerous  
34 United States and foreign intellectual property rights, including rights deriving from patents.  
35

36  
37 20. Prior to the introduction of the Clarisonic System, there were no sonic facial  
38 cleansing devices on the market. Indeed, before development of the Clarisonic System, no  
39 market existed for sonic skin care devices. PBL expended considerable resources to create the  
40 sonic skin care market and to educate the public regarding facial cleansing, as well as to market  
41 its sonic facial cleansing devices.  
42  
43  
44  
45

46  
47 21. Since its introduction, the Clarisonic System has become widely acclaimed by  
48 professionals and consumers, and has garnered many media awards from sources such as  
49 authoritative magazines in the beauty industry, Oprah's Favorite Things in 2007 on the Oprah  
50  
51

1 Winfrey Show, Best of Sephora in 2007 and 2008, and QVC Customer Choice in 2008, 2009,  
2 and 2010.  
3

4 22. The success of the Clarisonic System has spurred a large number of imitations,  
5 such as ANEX's Mimian, pictured below.  
6  
7



27  
28  
29 **V. PBL'S PATENTS**

30 **U.S. Patent No. 7,320,691**

31  
32 23. U.S. Patent No. 7,320,691 ("the '691 patent") issued on January 22, 2008, and is  
33 entitled "Apparatus and Method for Acoustic/Mechanical Treatment of Early Stage Acne." The  
34 inventors are Kenneth A. Pilcher, David Giuliani, and Stephen M. Meginniss.  
35  
36

37  
38 24. A copy of the '691 patent is attached as Exhibit 1.  
39

40 25. PBL is the exclusive licensee having all substantial rights in and to the '691  
41 patent, with the rights to bring enforcement actions for past, present and future infringement and  
42 to collect damages for past infringement.  
43  
44

45  
46 26. The '691 patent has been reexamined pursuant to Reexamination Request Nos.  
47 90/009,797 and 90/011,343. The patentability of all of the originally issued claims 1-52 of the  
48  
49  
50  
51

1 '691 patent was confirmed pursuant to these reexamination requests, and claims 53-64 were  
2 added. A reexamination certificate issued on September 20, 2011. *See* Exhibit 1.  
3

4 27. The '691 patent is valid, enforceable, and currently in full force and effect.  
5

6 **U.S. Patent No. 7,386,906**  
7

8 28. U.S. Patent No. 7,386,906 (“the '906 patent”) issued on June 17, 2008, and is  
9 entitled “Oscillating Brushhead Attachment System for a Personal Care Appliance.” The  
10 inventors are Dane M. Roth, Stephen M. Meginniss, III, Kenneth A. Pilcher, Richard A. Reishus,  
11 and David Giuliani.  
12

13 29. A copy of the '906 patent is attached as Exhibit 2.  
14

15 30. PBL is the exclusive licensee having all substantial rights in and to the '906  
16 patent, with the rights to bring enforcement actions for past, present and future infringement and  
17 to collect damages for past infringement.  
18

19 31. The '906 patent is valid, enforceable, and currently in full force and effect.  
20

21 **CLAIM I - INFRINGEMENT OF THE '691 PATENT**  
22

23 32. PBL hereby incorporates and realleges Paragraphs 1 - 31 as if fully set forth  
24 herein.  
25

26 33. ANEX has been and/or is directly infringing one or more claims of the '691  
27 patent pursuant to 35 U.S.C. § 271(a), literally or under the doctrine of equivalents, by making,  
28 using, offering to sell, and/or selling in the United States and/or importing into the United States,  
29 products, devices, or systems that are covered by the '691 patent, including the Mimian.  
30

31 34. PBL has consistently and continuously marked its products with the '691 patent  
32 number pursuant to 35 U.S.C. § 287 and has provided constructive notice of the '691 patent.  
33 PBL seeks monetary and all other damages permitted by statute.  
34

35 35. ANEX's infringement of the '691 patent has been and will continue to be willful  
36 and deliberate, by making, using, offering to sell, and/or selling in the United States and/or  
37 importing into the United States, infringing devices despite that such actions constitute  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

1 infringement and despite being at least on constructive notice that its actions constitute  
2 infringement.  
3

4 36. ANEX's infringement of the '691 patent has caused and will continue to cause  
5 PBL substantial and irreparable injury, for which PBL is entitled to all of the relief provided by  
6 35 U.S.C. §§ 281, 283, 284, and 285, including but not limited to injunctive relief, compensatory  
7 damages not less than the amount of a reasonable royalty, interest, costs, enhanced damages, and  
8 reasonable attorney's fees, as the court deems just and appropriate.  
9  
10

11 **CLAIM II - INFRINGEMENT OF THE '906 PATENT**

12 37. PBL hereby incorporates and realleges Paragraphs 1 - 36 as if fully set forth  
13 herein.  
14

15 38. ANEX has been and/or is directly infringing one or more claims of the '906  
16 patent pursuant to 35 U.S.C. § 271(a), literally or under the doctrine of equivalents, by making,  
17 using, offering to sell, and/or selling in the United States and/or importing into the United States,  
18 products, devices, or systems that are covered by the '906 patent, including the Mimian.  
19

20 39. PBL has consistently and continuously marked its products with the '906 patent  
21 number pursuant to 35 U.S.C. § 287 and has provided constructive notice of the '906 patent.  
22 PBL seeks monetary and all other damages permitted by statute.  
23

24 40. ANEX's infringement of the '906 patent has been and will continue to be willful  
25 and deliberate, by making, using, offering to sell, and/or selling in the United States and/or  
26 importing into the United States, infringing devices despite that such actions constitute  
27 infringement and despite being at least on constructive notice that its actions constitute  
28 infringement.  
29

30 41. ANEX's infringement of the '906 patent has caused and will continue to cause  
31 PBL substantial and irreparable injury, for which PBL is entitled to all of the relief provided by  
32 35 U.S.C. §§ 281, 283, 284, and 285, including but not limited to injunctive relief, compensatory  
33 damages not less than the amount of a reasonable royalty, interest, costs, enhanced damages, and  
34 reasonable attorney's fees, as the court deems just and appropriate.  
35



1 damages not less than the amount of a reasonable royalty, interest, costs, enhanced damages, and  
2 reasonable attorney's fees, as the court deems just and appropriate.  
3

4  
5 **VI. DEMAND FOR JURY TRIAL**

6  
7 42. Pursuant to Rule 38 of the Federal Rules of Civil Procedure, PBL respectfully  
8 requests a trial by jury of all issues properly triable by jury.  
9

10  
11 **VII. PRAYER FOR RELIEF**

12 WHEREFORE, PBL prays for relief, as follows:

- 13  
14 A. A judgment that ANEX has infringed one or more claims of the '691 patent;  
15  
16 B. A judgment that ANEX has infringed one or more claims of the '906 patent;  
17  
18 C. An order and judgment preliminarily and permanently enjoining ANEX and its  
19 officers, directors, agents, servants, employees, affiliates, attorneys, and all others acting in  
20 privity or in concert with them, and their investors, partners, parents, subsidiaries, divisions,  
21 successors, and assigns, from further acts of infringement of PBL's asserted patents;  
22  
23 D. A judgment awarding PBL all damages adequate to compensate for ANEX's  
24 infringement of PBL's asserted patents, and in no event less than a reasonable royalty for  
25 ANEX's acts of infringement, including all pre-judgment and post-judgment interest at the  
26 maximum rate permitted by law;  
27  
28 E. A judgment declaring that ANEX's infringement of the asserted patents has been  
29 willful and deliberate;  
30  
31 F. A judgment awarding PBL all damages, including treble damages, as a result of  
32 ANEX's willful and deliberate infringement of the asserted patents, pursuant to 35 U.S.C. § 284,  
33 together with pre-judgment and post-judgment interest;  
34  
35 G. A judgment declaring that this case is exceptional and awarding PBL its expenses,  
36 costs, and attorney's fees in accordance with 35 U.S.C. §§ 284 and 285 and Rule 54(d) of the  
37 Federal Rules of Civil Procedure; and  
38  
39 H. Such other and further relief as the Court deems just and proper.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51



1  
2 DATED: May 1, 2015.  
3

Respectfully submitted,

4 By: s/ Ramsey M. Al-Salam  
5 Ramsey M. Al-Salam WSBA #18822  
6 **Perkins Coie LLP**  
7 1201 Third Avenue, Suite 4900  
8 Seattle, WA 98101-3099  
9 Tel: (206) 359-8000  
10 Fax: (206) 359-9000  
11 Email: RAlsalam@perkinscoie.com

12  
13 Attorneys for Plaintiff  
14 Pacific Bioscience Laboratories, Inc.  
15

16 COUNSEL:  
17

18 Robert M. Masters (*pro hac to be submitted*)  
19 Timothy P. Cremen (*pro hac to be submitted*)  
20 Lisa Y. Leung (WSBA No. 43015)  
21 PAUL HASTINGS LLP  
22 875 15th St. NW  
23 Washington, D.C. 20005  
24 Tel: (202) 551-1700  
25 Fax: (202) 551-1705  
26 robertmasters@paulhastings.com  
27 timothy cremen@paulhastings.com  
28 lisaleung@paulhastings.com  
29

30 Robert L. Sherman (*pro hac to be submitted*)  
31 Natalie G. Furman (*pro hac to be submitted*)  
32 PAUL HASTINGS LLP  
33 75 East 55th Street  
34 New York, NY 10022  
35 Tel: (212) 318-6000  
36 Fax: (212) 230-7841  
37 robertsberman@paulhastings.com  
38 nataliefurman@paulhastngs.com  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51